The SARS-CoV-2 main protease is an important target for the development of COVID-19 therapeutics. Here, the authors combine X-ray crystallography and mass spectrometry and performed a large scale fragment screening campaign, which yielded 96 liganded structures of this essential viral protein that are of interest for further drug development efforts.
Communications Biology – Single-cell RNA-seq analysis integrated with ATAC-seq analysis of peripheral blood mononuclear cells demonstrates detailed immune cell profile in the onset of and…
Background The combination antimalarial artefenomel-piperaquine failed to achieve target efficacy in a phase 2b study in Africa and Vietnam. We retrospectively evaluated whether characterizing the…
Nature Communications – Lung tissue-resident memory T cells play critical roles in the response to and protection to subsequent re-exposure and infection with influenza viruses.…
The global dengue outbreak is a significant public health concern, with the World Health Organization recording over 3 million cases and a 0.04% case fatality…
Nature Communications – Untreated HIV infection results in CD4 depletion and progression towards immunosuppression, but the impact of successful antiretroviral treatment in HIV-positive people and…
A combination of bictegravir plus lenacapavir was well tolerated and highly effective in maintaining virologic suppression in people with human immunodefic
Immunology of Infectious Disease News is an online resource dedicated to covering the latest research and developments in the field of infectious diseases.
Immunology of Infectious Disease News is an online resource dedicated to covering the latest research and developments in the field of infectious diseases.
Abstract. Protein subunit vaccines form a key pipeline for developing novel tuberculosis (TB) vaccines. Mycobacterium tuberculosis (Mtb) contains approxima
Prevention of severe COVID-19 disease by SARS-CoV-2 in high-risk patients, such as immuno-compromised individuals, can be achieved by administration of antibody prophylaxis, but producing antibodies…
